FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3200217233> ?p ?o ?g. }

• W3200217233 endingPage "3015" @default.
• W3200217233 startingPage "2994" @default.
• W3200217233 abstract "Significance Statement A Task Force from the National Kidney Foundation and American Society of Nephrology developed recommendations for reassessing inclusion of race in the estimation of GFR in the United States. The Task Force recommends immediate implementation of the Chronic Kidney Disease Epidemiology Collaboration creatinine equation refit without the race variable in all laboratories because the calculation does not include race, it included diversity in its development, its potential adverse consequences do not disproportionately affect any one group, and it is immediately available to all laboratories. A second recommendation calls for national efforts to facilitate increased, routine, and timely use of cystatin C, especially to confirm eGFR in adults for clinical decision making. A third recommendation encourages research on GFR estimation with new endogenous filtration markers and interventions to eliminate racial and ethnic disparities. Background In response to a national call for re-evaluation of the use of race in clinical algorithms, the National Kidney Foundation (NKF) and the American Society of Nephrology (ASN) established a Task Force to reassess inclusion of race in the estimation of GFR in the United States and its implications for diagnosis and management of patients with, or at risk for, kidney diseases. Process & Deliberations The Task Force organized its activities over 10 months in phases to (1) clarify the problem and evidence regarding eGFR equations in the United States (described previously in an interim report), and, in this final report, (2) evaluate approaches to address use of race in GFR estimation, and (3) provide recommendations. We identified 26 approaches for the estimation of GFR that did or did not consider race and narrowed our focus, by consensus, to five of those approaches. We holistically evaluated each approach considering six attributes: assay availability and standardization; implementation; population diversity in equation development; performance compared with measured GFR; consequences to clinical care, population tracking, and research; and patient centeredness. To arrive at a unifying approach to estimate GFR, we integrated information and evidence from many sources in assessing strengths and weaknesses in attributes for each approach, recognizing the number of Black and non-Black adults affected. Recommendations (1) For US adults (>85% of whom have normal kidney function), we recommend immediate implementation of the CKD-EPI creatinine equation refit without the race variable in all laboratories in the United States because it does not include race in the calculation and reporting, included diversity in its development, is immediately available to all laboratories in the United States, and has acceptable performance characteristics and potential consequences that do not disproportionately affect any one group of individuals. (2) We recommend national efforts to facilitate increased, routine, and timely use of cystatin C, especially to confirm eGFR in adults who are at risk for or have CKD, because combining filtration markers (creatinine and cystatin C) is more accurate and would support better clinical decisions than either marker alone. If ongoing evidence supports acceptable performance, the CKD-EPI eGFR–cystatin C (eGFRcys) and eGFR creatinine–cystatin C (eGFRcr-cys_R) refit without the race variables should be adopted to provide another first-line test, in addition to confirmatory testing. (3) Research on GFR estimation with new endogenous filtration markers and on interventions to eliminate race and ethnic disparities should be encouraged and funded. An investment in science is needed for newer approaches that generate accurate, unbiased, and precise GFR measurement and estimation without the inclusion of race, and that promote health equity and do not generate disparate care. Implementation This unified approach, without specification of race, should be adopted across the United States. High-priority and multistakeholder efforts should implement this solution. Visual Abstract Export" @default.
• W3200217233 created "2021-09-27" @default.
• W3200217233 creator A5005930986 @default.
• W3200217233 creator A5005993471 @default.
• W3200217233 creator A5008698667 @default.
• W3200217233 creator A5011495488 @default.
• W3200217233 creator A5012206329 @default.
• W3200217233 creator A5032911571 @default.
• W3200217233 creator A5033928081 @default.
• W3200217233 creator A5041764283 @default.
• W3200217233 creator A5044235150 @default.
• W3200217233 creator A5049440508 @default.
• W3200217233 creator A5050833965 @default.
• W3200217233 creator A5050973509 @default.
• W3200217233 creator A5054296834 @default.
• W3200217233 date "2021-12-01" @default.
• W3200217233 modified "2023-10-18" @default.
• W3200217233 title "A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease" @default.
• W3200217233 cites W1550111394 @default.
• W3200217233 cites W1977364749 @default.
• W3200217233 cites W1995980728 @default.
• W3200217233 cites W2054072659 @default.
• W3200217233 cites W2055864845 @default.
• W3200217233 cites W2056503496 @default.
• W3200217233 cites W2058079128 @default.
• W3200217233 cites W2078010417 @default.
• W3200217233 cites W2089127343 @default.
• W3200217233 cites W2118625269 @default.
• W3200217233 cites W2118630425 @default.
• W3200217233 cites W2128168657 @default.
• W3200217233 cites W2128632384 @default.
• W3200217233 cites W2146841626 @default.
• W3200217233 cites W2155965977 @default.
• W3200217233 cites W2163578189 @default.
• W3200217233 cites W2284103617 @default.
• W3200217233 cites W2290365562 @default.
• W3200217233 cites W2318723339 @default.
• W3200217233 cites W2515465032 @default.
• W3200217233 cites W2757219124 @default.
• W3200217233 cites W286123195 @default.
• W3200217233 cites W2939222610 @default.
• W3200217233 cites W3010763889 @default.
• W3200217233 cites W3014342673 @default.
• W3200217233 cites W3033779685 @default.
• W3200217233 cites W3042894330 @default.
• W3200217233 cites W3055948184 @default.
• W3200217233 cites W3092668967 @default.
• W3200217233 cites W3100457878 @default.
• W3200217233 cites W3111410489 @default.
• W3200217233 cites W3130185842 @default.
• W3200217233 cites W3140363855 @default.
• W3200217233 cites W3149639442 @default.
• W3200217233 cites W3150595609 @default.
• W3200217233 cites W3153561131 @default.
• W3200217233 cites W3159456157 @default.
• W3200217233 cites W3162414317 @default.
• W3200217233 cites W3166972534 @default.
• W3200217233 cites W3193807166 @default.
• W3200217233 cites W4226390647 @default.
• W3200217233 doi "https://doi.org/10.1681/asn.2021070988" @default.
• W3200217233 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34556489" @default.
• W3200217233 hasPublicationYear "2021" @default.
• W3200217233 type Work @default.
• W3200217233 sameAs 3200217233 @default.
• W3200217233 citedByCount "131" @default.
• W3200217233 countsByYear W32002172332021 @default.
• W3200217233 countsByYear W32002172332022 @default.
• W3200217233 countsByYear W32002172332023 @default.
• W3200217233 crossrefType "journal-article" @default.
• W3200217233 hasAuthorship W3200217233A5005930986 @default.
• W3200217233 hasAuthorship W3200217233A5005993471 @default.
• W3200217233 hasAuthorship W3200217233A5008698667 @default.
• W3200217233 hasAuthorship W3200217233A5011495488 @default.
• W3200217233 hasAuthorship W3200217233A5012206329 @default.
• W3200217233 hasAuthorship W3200217233A5032911571 @default.
• W3200217233 hasAuthorship W3200217233A5033928081 @default.
• W3200217233 hasAuthorship W3200217233A5041764283 @default.
• W3200217233 hasAuthorship W3200217233A5044235150 @default.
• W3200217233 hasAuthorship W3200217233A5049440508 @default.
• W3200217233 hasAuthorship W3200217233A5050833965 @default.
• W3200217233 hasAuthorship W3200217233A5050973509 @default.
• W3200217233 hasAuthorship W3200217233A5054296834 @default.
• W3200217233 hasBestOaLocation W32002172332 @default.
• W3200217233 hasConcept C126322002 @default.
• W3200217233 hasConcept C137403100 @default.
• W3200217233 hasConcept C159641895 @default.
• W3200217233 hasConcept C162324750 @default.
• W3200217233 hasConcept C17744445 @default.
• W3200217233 hasConcept C177713679 @default.
• W3200217233 hasConcept C187736073 @default.
• W3200217233 hasConcept C199539241 @default.
• W3200217233 hasConcept C2778653478 @default.
• W3200217233 hasConcept C54847362 @default.
• W3200217233 hasConcept C71924100 @default.
• W3200217233 hasConcept C96250715 @default.
• W3200217233 hasConceptScore W3200217233C126322002 @default.
• W3200217233 hasConceptScore W3200217233C137403100 @default.
• W3200217233 hasConceptScore W3200217233C159641895 @default.

• next